Noninfectious Complications of Peritoneal Dialysis

Jones, Colin L.; Roumeliotis, Athanasios; Bargman, Joanne M.

doi:10.1016/b978-0-323-52978-5.00033-1

Cited by 1 publication

(2 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of EPS varies widely, with the highest reported incidence being 19.4%, whereas more recent studies have reported lower rates ranging from 0.5% to 4.4% [ 13 ]. This high variability in event rates is due to differences in the duration of PD.…”

Section: Introductionmentioning

confidence: 99%

“…The mortality rate among PD users with EPS has been reported to range from 38 to 83%, but in more recent studies, survival may vary from 6 to 48 months or from 26 to 56%. This EPS mortality rate is also related to the duration of PD [ 13 , 15 ]. Because of the magnitude of the impact that peritoneal fibrosis can have on the quality of life of PD users, it is important to better understand and tackle this complication.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current Insights into Cellular Determinants of Peritoneal Fibrosis in Peritoneal Dialysis: A Narrative Review

Suryantoro

Wungu

Sutanto

et al. 2023

JCM

View full text Add to dashboard Cite

Peritoneal fibrosis is the final process of progressive changes in the peritoneal membrane due to chronic inflammation and infection. It is one of the main causes of discontinuation of peritoneal dialysis (PD), apart from peritonitis and cardiovascular complications. Over time, morphological changes occur in the peritoneal membranes of patients who use PD. Of those are mesothelial-to-mesenchymal transition (MMT), neoangiogenesis, sub-mesothelial fibrosis, and hyalinizing vasculopathy. Several key molecules are involved in the complex pathophysiology of peritoneal fibrosis, including advanced glycosylation end products (AGEs), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF). This narrative review will first discuss the physiology of the peritoneum and PD. Next, the multifaceted pathophysiology of peritoneal fibrosis, including the effects of hyperglycemia and diabetes mellitus on the peritoneal membrane, and the promising biomarkers of peritoneal fibrosis will be reviewed. Finally, the current and future management of peritoneal fibrosis will be discussed, including the potential benefits of new-generation glucose-lowering medications to prevent or slow down the progression of peritoneal fibrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%